Neurology

Clinical Update

Nuplazid: Novel Mechanism, Modest Benefits

Topics: Dopamine | Geriatric Psychiatry | Neurology | Novel Medications | Nuplazid | Parkinson’s

Psychosis can be a paralyzing dilemma for patients with Parkinson’s disease (PD). Most antipsychotics worsen the motor symptoms of PD, while the dopaminergic drugs that treat PD can worsen the psychosis. Psychosis afflicts up to 60% of patients with PD, and it is the leading cause of nursing home placement in these patients (Hacksell U et al, Neuroche

Read More
Research Update

Antipsychotics Fall Short in Delirium

Topics: Dopamine | Geriatric Psychiatry | Neurology | Novel Medications | Nuplazid | Parkinson’s

Review: Oh ES et al, Ann Intern Med 2019;171(7):474–484; Nikooie R et al, Ann Intern Med 2019;171(7):485–495 Study type: Systematic reviews of randomized controlled trials and prospective studies Delirium is common and costly. With an incidence rate approaching 50% in hospitalized older adults, the condition poses a burden that is anticipated

Read More
News of Note

Meet the First H3 Antagonist

Topics: Histamine | Narcolepsy | Neurology | News of Note | Pitolisant | Wakix

On August 15, 2019, pitolisant (Wakix) received FDA approval for narcolepsy, making it the first release of a histamine-3 (H3) antagonist. Unlike other narcolepsy medications, pitolisant is not a controlled substance and lacks abuse potential. Those other options for narcolepsy are the stimulants (methylphenidate and amphetamine), the modafinils, sodiu

Read More